Market capitalization | AUD2.46b |
Enterprise Value | AUD2.60b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 302.41 |
P/S ratio (TTM) P/S ratio | 285.85 |
P/B ratio (TTM) P/B ratio | 2.99 |
Revenue (TTM) Revenue | AUD8.59m |
EBIT (operating result TTM) EBIT | AUD-78.52m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
6 Analysts have issued a Mesoblast forecast:
6 Analysts have issued a Mesoblast forecast:
Dec '24 |
+/-
%
|
||
Revenue | 8.59 8.59 |
25%
25%
|
|
Gross Profit | 14 14 |
150%
150%
|
|
EBITDA | -72 -72 |
-
|
EBIT (Operating Income) EBIT | -79 -79 |
27%
27%
|
Net Profit | -157 -157 |
28%
28%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Silviu Itescu |
Employees | 73 |
Founded | 2004 |
Website | www.mesoblast.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.